Laser treatment for diabetic macular edema and proliferative diabetic retinopathy has been the mainstay for several decades. Both are described and illustrated.
Vascular endothelial growth factor is implicated to cause loss of vision in both diabetic retinopathy and macular degeneration. Review of how VEGF works and effect treatments for diabetic retinopathy and macular degeneration.
Lucentis is the second anti-VEGF drug FDA approved for the treatment of wet macular degeneration. It is an effective treatment for wet macular degeneration. The formulation differs from Macugen and Avastin as do the visual results.